Effects of the allosteric tyrosine kinase inhibitor asciminib on bone metabolism
Klinische Pädiatrie · 01.05.2024 · 236 (03) · 205
DOI: 10.1055/s-0044-1786576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.05.2024. Verfasst von T Fuhrmann und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) treatment using tyrosine kinase inhibitors (TKIs) poses impaired longitudinal growth in pediatric patients. Alternative therapeutic concepts such as a more selective inhibition of ABL1 kinase by the allosteric inhibitor asciminib could be particularly beneficial in children. We therefore compared in vitro the impact on bone metabolism of asciminib to the current first- and second-line TKIs imatinib and dasatinib. Asciminib had a lower impact on osteoclast viability, differentiation, and function and did not affect the mineralization capacity of osteoblasts in contrast to the other TKIs. While imatinib and dasatinib significantly inhibit osteoclast differentiation and function, no significant effects were observed for asciminib. Our findings suggest asciminib as an ABL1 kinase inhibitor with fewer side effects on bone metabolism, potentially improving longitudinal growth. Publication History Article published online: 10 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Fuhrmann, T., Krumbholz, M., Steffen, U., Sembill, S., & Metzler, M. (2024). Effects of the allosteric tyrosine kinase inhibitor asciminib on bone metabolism. Klinische Pädiatrie, 236(03), 205. https://doi.org/10.1055/s-0044-1786576
Vancouver
Fuhrmann T, Krumbholz M, Steffen U, Sembill S, Metzler M. Effects of the allosteric tyrosine kinase inhibitor asciminib on bone metabolism. Klinische Pädiatrie. 2024;236(03):205. doi:10.1055/s-0044-1786576
BibTeX
@article{Fuhrmann2024,
author = {Fuhrmann, T and Krumbholz, M and Steffen, U and Sembill, S and Metzler, M},
title = {Effects of the allosteric tyrosine kinase inhibitor asciminib on bone metabolism},
journal = {Klinische Pädiatrie},
year = {2024},
volume = {236},
number = {03},
pages = {205},
doi = {10.1055/s-0044-1786576}
}
EUVIMED